EPIGENOMICS AG (ECX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ECX - DE000A37FT41 - Common Stock
0.7 EUR
-0.09 (-11.17%)
Taking everything into account, ECX scores 2 out of 10 in our fundamental rating. ECX was compared to 86 industry peers in the Biotechnology industry. ECX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ECX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- ECX had negative earnings in the past year.
- ECX had a negative operating cash flow in the past year.
1.2 Ratios
- ECX has a Return On Assets of -386.29%. This is amonst the worse of the industry: ECX underperforms 92.00% of its industry peers.
- The Return On Equity of ECX (-853.33%) is worse than 73.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -386.29% | ||
| ROE | -853.33% | ||
| ROIC | N/A |
ROA(3y)-85.87%
ROA(5y)-87.49%
ROE(3y)-143.87%
ROE(5y)-135.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 76.56%, ECX is doing good in the industry, outperforming 78.67% of the companies in the same industry.
- In the last couple of years the Gross Margin of ECX has declined.
- ECX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.98%
GM growth 5Y-2.81%
2. Health
2.1 Basic Checks
- ECX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ECX has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for ECX is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -44.22, we must say that ECX is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -44.22, ECX is not doing good in the industry: 93.33% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.06 indicates that ECX is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.06, ECX is in the better half of the industry, outperforming 73.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -44.22 |
ROIC/WACCN/A
WACC3.9%
2.3 Liquidity
- ECX has a Current Ratio of 1.93. This is a normal value and indicates that ECX is financially healthy and should not expect problems in meeting its short term obligations.
- ECX has a Current ratio (1.93) which is comparable to the rest of the industry.
- A Quick Ratio of 1.93 indicates that ECX should not have too much problems paying its short term obligations.
- With a Quick ratio value of 1.93, ECX perfoms like the industry average, outperforming 50.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
- The earnings per share for ECX have decreased strongly by -7359.64% in the last year.
- ECX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.80%.
- ECX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -23.61% yearly.
EPS 1Y (TTM)-7359.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3779.63%
Revenue 1Y (TTM)-92.8%
Revenue growth 3Y-24.46%
Revenue growth 5Y-23.61%
Sales Q2Q%-44.44%
3.2 Future
- ECX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.99% yearly.
- ECX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 108.06% yearly.
EPS Next Y47.75%
EPS Next 2Y39.12%
EPS Next 3Y25.12%
EPS Next 5Y17.99%
Revenue Next Year2136.83%
Revenue Next 2Y-36.75%
Revenue Next 3Y-25.99%
Revenue Next 5Y108.06%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- ECX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ECX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as ECX's earnings are expected to grow with 25.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.12%
EPS Next 3Y25.12%
5. Dividend
5.1 Amount
- ECX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPIGENOMICS AG / ECX.DE FAQ
What is the ChartMill fundamental rating of EPIGENOMICS AG (ECX.DE) stock?
ChartMill assigns a fundamental rating of 2 / 10 to ECX.DE.
What is the valuation status for ECX stock?
ChartMill assigns a valuation rating of 1 / 10 to EPIGENOMICS AG (ECX.DE). This can be considered as Overvalued.
Can you provide the profitability details for EPIGENOMICS AG?
EPIGENOMICS AG (ECX.DE) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for ECX stock?
The Earnings per Share (EPS) of EPIGENOMICS AG (ECX.DE) is expected to grow by 47.75% in the next year.